Thozhukat Sathyapalan T.Sathyapalan@hull.ac.uk
Disparate effects of atorvastatin compared with simvastatin on C-reactive protein concentrations in patients with Type 2 diabetes
Sathyapalan, Thozhukat; Atkin, Stephen L.; Kilpatrick, Eric S.
Stephen L. Atkin
Eric S. Kilpatrick
OBJECTIVE - Reduction in LDL and high sensitivity (hs) C-reactive protein (CRP) are independent indicators of successful cardiovascular risk reduction with statins. This study compared the effect of equivalent LDL-lowering doses of simvastatin and atorvastatin on hsCRP in type 2 diabetic patients. RESEARCH DESIGN AND METHODS - A crossover study of 26 patients with type 2 diabetes taking either 40 mg simvastatin or 10 mg atorvastatin was undertaken. After 3 months on one statin, lipids and hsCRP were measured on 10 occasions over a 5-week period. The same procedure was then followed taking the other statin. RESULTS - LDL was comparable on either treatment: atorvastatin 2.2 +/- 0.2 vs. 2.1 +/- 0.3 mmol/l (mean +/- SD; P = 0.19). CRP of individuals taking atorvastatin was significantly lower than when they were taking simvastatin (median 1.08 vs. 1.47 mg/l, P = 0.0002) and was less variable (median SD of logCRP 0.0036 vs. 0.178, P = 0.0001). CONCLUSIONS - Compared with simvastatin, atorvastatin reduced hsCRP and its variability in type 2 diabetic patients. This enhanced anti-inflammatory effect may prove beneficial if lower CRP is associated with improved cardiovascular risk.
|Journal Article Type||Article|
|Publication Date||Sep 1, 2010|
|Publisher||American Diabetes Association|
|Peer Reviewed||Peer Reviewed|
|APA6 Citation||Sathyapalan, T., Atkin, S. L., & Kilpatrick, E. S. (2010). Disparate effects of atorvastatin compared with simvastatin on C-reactive protein concentrations in patients with Type 2 diabetes. Diabetes Care, 33(9), 1948-1950. doi:10.2337/dc10-0201|
|Keywords||Internal Medicine; Endocrinology, Diabetes and Metabolism; Advanced and Specialised Nursing|
© 2010 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
You might also like
Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes